復宏漢霖(02696.HK):注射用HLX43(靶向PD-L1抗體-新型DNA拓撲異構酶I抑制劑偶聯藥物)聯合漢斯狀(斯魯利單抗注射液)治療晚期/轉移性實體瘤患者的1b/2期臨牀試驗申請獲國家藥品監督管理局批准
格隆匯1月10日丨復宏漢霖(02696.HK)公吿,近日,注射用HLX43(靶向PD-L1抗體-新型DNA拓撲異構酶I抑制劑偶聯藥物)(HLX43)聯合漢斯狀(斯魯利單抗注射液)治療晚期/轉移性實體瘤患者的1b/2期臨牀試驗申請獲國家藥品監督管理局(NMPA)批准。
臨牀前及臨牀資料表明抗體偶聯藥物(ADC)和PD-1/L1單克隆抗體聯合用藥可產生協同增效作用,該聯合治療有望給患者帶來更加有效及安全的臨牀解決方案。
截至本公吿日,於全球範圍內尚無同類聯合用藥方案獲批上市。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.